Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount of weight, the company said.

Eli Lilly says their obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for approval. Patients taking the pill called orforglipron, an oral GLP-1 receptor, lost almost 12% of their body weight,

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.